Patents by Inventor Thomas Christoph

Thomas Christoph has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210273380
    Abstract: An electrical plug-in connector for differential signal transmission, having an external conductor contact element, a dielectric and at least one internal conductor contact element pair for differential signal transmission. The dielectric extends along a longitudinal axis through the external conductor contact element. The internal conductor contact element pair has a first internal conductor contact element and a second internal conductor contact element which extend along the longitudinal axis through the dielectric. The external conductor contact element and/or the dielectric have a compensation geometry in order to compensate for an asymmetry of the internal conductor contact element pair with respect to the longitudinal axis. As an alternative or in addition, it is provided that the internal conductor contact element pair has a compensation geometry in order to compensate for an asymmetry of the external conductor contact element and/or of the dielectric with respect to the longitudinal axis.
    Type: Application
    Filed: February 16, 2021
    Publication date: September 2, 2021
    Inventors: Thomas Unterhauser, Georg Christoph Michael Lochner, Martin Arthur Kositza
  • Publication number: 20210212967
    Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 15, 2021
    Applicant: Gruenenthal GmbH
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE, Thomas CHRISTOPH, Wolfgang SCHROEDER
  • Publication number: 20200215003
    Abstract: An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Applicant: GRÜNENTHAL GMBH
    Inventors: Thomas CHRISTOPH, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS, Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Petra BLOMS-FUNKE, Klaus SCHIENE, Ulrich FEIL
  • Publication number: 20190388360
    Abstract: The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain, wherein the pain is neuropathic pain or wherein the pain has a neuropathic pain component. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 26, 2019
    Applicant: TEIKOKU SEIYAKU CO., LTD.
    Inventors: Antonio NARDI, Klaus SCHIENE, Thomas CHRISTOPH, Sebastian WACHTEN, Irmgard BÖSL, Andreas SCHOLZ, Ingo FRIEDRICH, Sebastian ULLRICH, Simone KÖNIG
  • Publication number: 20190388364
    Abstract: The invention relates to a pharmaceutical composition comprising Tapentadol or a physiologically acceptable salt thereof for use in local anesthesia.
    Type: Application
    Filed: August 20, 2019
    Publication date: December 26, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Johannes SCHNEIDER, Thomas CHRISTOPH
  • Publication number: 20190374481
    Abstract: The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 12, 2019
    Applicant: TEIKOKU SEIYAKU CO., LTD.
    Inventors: Antonio NARDI, Klaus SCHIENE, Thomas CHRISTOPH, Sebastian WACHTEN, Irmgard BÖSL, Andreas SCHOLZ, Ingo FRIEDRICH, Sebastian ULLRICH, Simone KÖNIG
  • Publication number: 20190274974
    Abstract: The use of tapentadol for the treatment of pain associated with disorders of the trigeminal nerve, in particular for use in the treatment of pain associated with trigeminal neuralgia.
    Type: Application
    Filed: May 28, 2019
    Publication date: September 12, 2019
    Applicant: GRUENENTHAL GMBH
    Inventors: Thomas CHRISTOPH, Jean De Vry, Thomas Tzschentke, Petra Bloms-Funke, Klaus Schiene, Michel Hamon
  • Patent number: 10328055
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro [cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an antidepressant.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: June 25, 2019
    Assignee: GRUENENTHAL GMBH
    Inventors: Stefanie Frosch, Klaus Linz, Thomas Christoph
  • Publication number: 20190133971
    Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.
    Type: Application
    Filed: January 3, 2019
    Publication date: May 9, 2019
    Applicant: GRUENENTHAL GMBH
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE, Thomas CHRISTOPH
  • Patent number: 10206890
    Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: February 19, 2019
    Assignee: GRUENENTHAL GMBH
    Inventors: Klaus Schiene, Petra Bloms-Funke, Thomas Christoph
  • Publication number: 20180200205
    Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.
    Type: Application
    Filed: March 15, 2018
    Publication date: July 19, 2018
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE, Thomas CHRISTOPH, Wolfgang SCHROEDER
  • Patent number: 9771359
    Abstract: The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: September 26, 2017
    Assignee: Medifron DBT Inc.
    Inventors: Robert Frank-Foltyn, Christopher Habermann, Gregor Bahrenberg, Bernhard Lesch, Nils Damann, Klaus Schiene, Hannelore Stockhausen, Thomas Christoph, Sven Frormann, Derek Saunders, Jeewoo Lee
  • Publication number: 20170253586
    Abstract: The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Application
    Filed: May 23, 2017
    Publication date: September 7, 2017
    Inventors: Robert FRANK-FOLTYN, Christopher HABERMANN, Gregor BAHRENBERG, Bernhard LESCH, Nils DAMANN, Klaus SCHIENE, Hannelore STOCKHAUSEN, Thomas CHRISTOPH, Sven FRORMANN, Derek SAUNDERS, Jeewoo LEE
  • Publication number: 20170216226
    Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.
    Type: Application
    Filed: April 13, 2017
    Publication date: August 3, 2017
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE, Thomas CHRISTOPH, Wolfgang SCHROEDER
  • Patent number: 9629825
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 25, 2017
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Thomas Christoph
  • Patent number: 9624209
    Abstract: Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: April 18, 2017
    Assignee: Gruenenthal GmbH
    Inventors: Robert Frank-Foltyn, Gregor Bahrenberg, Thomas Christoph, Klaus Schiene, Jean De Vry, Nils Damann, Sven Frormann, Bernhard Lesch, Jeewoo Lee, Yong-Soo Kim, Myeong-Seop Kim, Derek Saunders, Hannelore Stockhausen
  • Publication number: 20170065560
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro [cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an antidepressant.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 9, 2017
    Inventors: Stefanie Frosch, Klaus LINZ, Thomas CHRISTOPH
  • Publication number: 20170042836
    Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE, Thomas CHRISTOPH, Wolfgang SCHROEDER
  • Publication number: 20160193183
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.
    Type: Application
    Filed: March 15, 2016
    Publication date: July 7, 2016
    Inventors: Stefanie FROSCH, Klaus LINZ, Thomas CHRISTOPH
  • Patent number: 9345689
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an anticonvulsant selected from the group consisting of retigabin, lamotrigine, lacosamide, levetiracetam, carbamazepine, sultiame, phenacemide, felbamate, topiramate, pheneturide, brivaracetam, selectracetam, zonisamide, stiripentol, beclamide, mexiletin, ralfinamide, methylphenobarbital, phenobarbital, primidone, barbexaclone, metharbital, ethotoin, phenyloin, amino(diphenylhydantoin) valeric acid, mephenyloin, fosphenyloin, paramethadione, trimethadione, ethadione, ethosuximide, phensuximide, mesuximide, clonazepam, lorazepam, diazepam, clobazam, oxcarbazepine, eslicarbazepine, rufinamide, valproic acid, valpromide, aminobutyric acid, progabide, tiagabine, and the physiolo
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: May 24, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Thomas Christoph